BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28045749)

  • 1. Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.
    Chou S; Hwang SJ; Carlos G; Wakade D; Fernandez-Penas P
    Am J Dermatopathol; 2017 Jan; 39(1):23-27. PubMed ID: 28045749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
    Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
    Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
    Shi VJ; Rodic N; Gettinger S; Leventhal JS; Neckman JP; Girardi M; Bosenberg M; Choi JN
    JAMA Dermatol; 2016 Oct; 152(10):1128-1136. PubMed ID: 27411054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
    Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
    J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy.
    Martínez-Doménech Á; García-Legaz Martínez M; Magdaleno-Tapial J; Valenzuela-Oñate C; Pérez-Pastor G; Pérez-Ferriols A
    Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
    Obara K; Masuzawa M; Amoh Y
    J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.
    Schaberg KB; Novoa RA; Wakelee HA; Kim J; Cheung C; Srinivas S; Kwong BY
    J Cutan Pathol; 2016 Apr; 43(4):339-46. PubMed ID: 26762844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
    JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
    Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS
    J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
    Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
    J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
    J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer.
    Diaz-Perez JA; Beveridge MG; Victor TA; Cibull TL
    J Cutan Pathol; 2018 Jun; 45(6):434-438. PubMed ID: 29468713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab-induced lichenoid dermatitis occurring in a patient with metastatic melanoma successfully treated with alitretinoin.
    Edwards C; Fearfield L
    Clin Exp Dermatol; 2018 Jul; 43(5):609-610. PubMed ID: 29453770
    [No Abstract]   [Full Text] [Related]  

  • 14. PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-Report of 4 cases.
    Chou S; Zhao C; Hwang SJE; Fernandez-Penas P
    J Cutan Pathol; 2017 Oct; 44(10):851-856. PubMed ID: 28753231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terbinafine-induced lichenoid drug eruption: case report and review of terbinafine-associated cutaneous adverse events.
    Cohen PR; Erickson CP; Calame A
    Dermatol Online J; 2020 Jul; 26(7):. PubMed ID: 32898398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertrophic lichenoid eruption due to furosemide.
    Arias-Santiago S; Aneiros-Fernandez J; Aceituno-Madera P; Burkhardt-Perez P; Naranjo Sintes R
    Acta Derm Venereol; 2010; 90(1):78-9. PubMed ID: 20107731
    [No Abstract]   [Full Text] [Related]  

  • 17. Terbinafine-induced lichenoid drug eruption.
    Zheng Y; Zhang J; Chen H; Lai W; Maibach HI
    Cutan Ocul Toxicol; 2017 Mar; 36(1):101-103. PubMed ID: 26938740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect.
    Garcovich S; Burlando M; Rongioletti F; Garcovich A; Parodi A; Amerio P
    Acta Derm Venereol; 2010 May; 90(3):311-2. PubMed ID: 20526559
    [No Abstract]   [Full Text] [Related]  

  • 19. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature.
    Kuraishi N; Nagai Y; Hasegawa M; Ishikawa O
    Acta Derm Venereol; 2010; 90(1):73-6. PubMed ID: 20107730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
    Hwang SJE; Fernández-Peñas P
    Curr Probl Dermatol; 2018; 53():82-92. PubMed ID: 29131040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.